Genmab — Januar 2014
-
We continue to believe
that the biotech industry is in the early innings of an innovation cycle with many labelexpansion
opportunities and novel agents in phase 2 or 3 trials that are largely
unaccounted for in Street models. Hence, we are bullish on the group for 2014. -
Genmab er den usynlige engine der skaber produkterne
de andre tager fame for dem -
næh - gode nyheder. Kempen hæver kursmål fra 200 til 285
-
Ja, i allerhøjeste grad. GEN vælter rundt uden retning, og der bliver spundet alle mulige historier. I dag er GS en af de store købere og NDA en af de store sælgere... Det giver ikke rigtig mening
-
en lille hurtig FDA godkendelse vil gøre underværker. Så kan der måske komme gang i lidt flere kombo-forsøg med arzerra
-
ja selvfølgelig er det det - vi har jo ikke noget at holde os til. Mon ikke det er data på Maintenance, der er først på affyringsblokken?
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind